Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

Belch, J. J. F.; Brodmann, Marianne; Baumgartner, Iris; Binder, Christoph J.; Casula, Manuela; Heiß, Christian; Kahan, Thomas; Parini, Paolo; Poredoš, Pavel; Catapano, Alberico L.; Tokgözoğlu, Lâle

doi:10.1016/j.atherosclerosis.2021.09.022

Cited by 11 publications

(5 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Statins are recommended as first-line therapy in the treatment of patients with PAD to decrease the lipid plaque burden and reduce the risk of adverse CV events [6,7]. Statins competitively inhibit 3-β-Hydroxy β-methylglutaryl-CoA reductase, which is an enzyme responsible for the synthesis of mevalonic acid.…”

Section: Role Of Statins In Pad 41 Mechanism Of Action Of Statinsmentioning

confidence: 99%

“…A high-intensity statin, at the highest tolerated dose, should be prescribed as first-line therapy given the evidence showing reductions in MALE and MACE. Addition of ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is recommended if the LDL-C remains above goal (based on the degree of risk, ESC guidelines give a goal of either <55 or <40 mg/dL in those with recurrent ASCVD events) [7]. The multi-society guidelines for management of patients in 2018 classified PAD as an ASCVD equivalent alongside MI, stroke, and CAD [50].…”

Section: Current Guidelinesmentioning

confidence: 99%

“…Regardless of symptoms, PAD is a strong harbinger of associated current or future CV disease and major adverse CV events (MACE). As an example, stroke and myocardial infarction (MI) are three and four times more likely, respectively, in patients suffering from PAD [5][6][7]. A reduced ABI has a two-fold higher risk of MI, angina, congestive heart failure, and cerebrovascular disease [8]; overall mortality in PAD correlates strongly with a decline in the ABI [9].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of Lipid-Lowering Therapy in Peripheral Artery Disease

Belur

Shah

Virani

et al. 2022

JCM

View full text Add to dashboard Cite

Atherosclerosis is a multifactorial, lipoprotein-driven condition that leads to plaque formation within the arterial tree, leading to subsequent arterial stenosis and thrombosis that accounts for a large burden of cardiovascular morbidity and mortality globally. Atherosclerosis of the lower extremities is called peripheral artery disease and is a major cause of loss in mobility, amputation, and critical limb ischemia. Peripheral artery disease is a common condition with a gamut of clinical manifestations that affects an estimated 10 million people in the United States of America and 200 million people worldwide. The role of apolipoprotein B-containing lipoproteins, such as LDL and remnant lipoproteins in the development and progression of atherosclerosis, is well-established. The focus of this paper is to review existing data on lipid-lowering therapies in lower extremity atherosclerotic peripheral artery disease.

show abstract

Section: Role Of Statins In Pad 41 Mechanism Of Action Of Statinsmentioning

confidence: 99%

Section: Current Guidelinesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Lipid-Lowering Therapy in Peripheral Artery Disease

Belur

Shah

Virani

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Further, statin treatment has been reported to reduce all-cause mortality by 39 %, CV death by 41 %, CV outcomes by 34 % and ischaemic stroke by 28 %, but also reduced acute limb ischaemia by 30 % and amputations by 35 %. 16 …”

Section: Introductionmentioning

confidence: 99%

“… 30 Thus the FOURIER was the first randomized trial to demonstrate that intensive LDL-C lowering was safe and effective in decreasing the risk of acute limb ischaemia. 16 Similarly, in Alirucumab and cardiovascular outcome after acute coronary syndrome (ODYSSEY) trial wherein primary endpoint was composite death with a median follow up of 2.8 years. In this study, patients on high intensity statins were randomized to receive alirocumab or placebo with dose adjustment every 2 weeks.…”

Section: Introductionmentioning

confidence: 99%